PL1951274T3 - Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka - Google Patents

Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka

Info

Publication number
PL1951274T3
PL1951274T3 PL06806214T PL06806214T PL1951274T3 PL 1951274 T3 PL1951274 T3 PL 1951274T3 PL 06806214 T PL06806214 T PL 06806214T PL 06806214 T PL06806214 T PL 06806214T PL 1951274 T3 PL1951274 T3 PL 1951274T3
Authority
PL
Poland
Prior art keywords
parapoxviruses
biochemotherapy
cancer
treatment
combination
Prior art date
Application number
PL06806214T
Other languages
English (en)
Inventor
Olaf Weber
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37654955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1951274(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of PL1951274T3 publication Critical patent/PL1951274T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/768Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24211Parapoxvirus, e.g. Orf virus
    • C12N2710/24232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
PL06806214T 2005-11-24 2006-10-12 Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka PL1951274T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05025600 2005-11-24
EP06806214A EP1951274B1 (en) 2005-11-24 2006-10-12 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
PCT/EP2006/009855 WO2007059821A1 (en) 2005-11-24 2006-10-12 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL1951274T3 true PL1951274T3 (pl) 2010-05-31

Family

ID=37654955

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06806214T PL1951274T3 (pl) 2005-11-24 2006-10-12 Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka

Country Status (15)

Country Link
US (1) US7897159B2 (pl)
EP (1) EP1951274B1 (pl)
JP (1) JP5164849B2 (pl)
CN (1) CN101312737B (pl)
AR (1) AR057922A1 (pl)
AT (1) ATE450266T1 (pl)
CA (1) CA2630833C (pl)
DE (1) DE602006010902D1 (pl)
DK (1) DK1951274T3 (pl)
ES (1) ES2335308T3 (pl)
HK (1) HK1117427A1 (pl)
PL (1) PL1951274T3 (pl)
PT (1) PT1951274E (pl)
TW (1) TWI415617B (pl)
WO (1) WO2007059821A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
PL2326329T3 (pl) 2008-08-04 2017-07-31 Wyeth Llc Przeciwnowotworowe połączenia 4-anilino-3-cyjanochinolin i kapecytabiny
WO2010117633A1 (en) 2009-04-06 2010-10-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3816139A1 (de) 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
SK362003A3 (en) * 2000-07-11 2003-07-01 Bayer Ag Use of strains of the Parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
NZ512341A (en) * 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
WO2004014314A2 (en) * 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer

Also Published As

Publication number Publication date
US7897159B2 (en) 2011-03-01
JP5164849B2 (ja) 2013-03-21
CN101312737A (zh) 2008-11-26
JP2009517347A (ja) 2009-04-30
US20090035269A1 (en) 2009-02-05
DK1951274T3 (da) 2010-02-01
PT1951274E (pt) 2009-12-14
AR057922A1 (es) 2007-12-26
EP1951274B1 (en) 2009-12-02
WO2007059821A1 (en) 2007-05-31
HK1117427A1 (en) 2009-01-16
DE602006010902D1 (de) 2010-01-14
ES2335308T3 (es) 2010-03-24
EP1951274A1 (en) 2008-08-06
CA2630833C (en) 2015-01-06
CN101312737B (zh) 2012-11-14
TW200738250A (en) 2007-10-16
CA2630833A1 (en) 2007-05-31
TWI415617B (zh) 2013-11-21
ATE450266T1 (de) 2009-12-15

Similar Documents

Publication Publication Date Title
HUS1700015I1 (hu) PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél
IL186662A0 (en) Combination cancer therapy with
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
IL201211A (en) K3 ip-alpha quinoxaline inhibitors for use in combination with chemotherapeutic agents for use in the treatment of cancer
EP1940456A4 (en) WWOX GENE, VECTORS COMPRISING THE SAME, AND USES THEREOF IN THE TREATMENT OF CANCER
SI2358697T1 (sl) Spojine izoindolina za uporabo pri zdravljenju raka
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
EP1868435A4 (en) COMBINATIONS, METHODS AND COMPOSITIONS FOR TREATING CANCER
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
PL2564872T3 (pl) Mazindol sam lub w kombinacji z żelazem do leczenia deficytu uwagi/nadpobudliwości
HK1117427A1 (en) Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
EP1891047A4 (en) A 1-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID SUITABLE FOR THE CHEMOTHERAPY OF CANCER
EP1952811A4 (en) USE OF ERIOCALYXIN B FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LEUKEMIA
GB0517387D0 (en) Combinations for the treatment of cancer
HK1151971A1 (en) Compounds for use in the treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
AU307436S (en) Angle grinder
AU303295S (en) Belt
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
EP1917041A4 (en) USE OF FRUCTOSE-BASED THERAPIES FOR CANCER TREATMENT
IL185518A0 (en) 1,3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents